• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dis . Low levels of post-vaccination hemagglutination inhibition antibodies and their correlation with influenza protection among healthcar

tetano

Editor, Senior Moderator
J Infect Dis


. 2025 Apr 10:jiaf183.
doi: 10.1093/infdis/jiaf183. Online ahead of print. Low levels of post-vaccination hemagglutination inhibition antibodies and their correlation with influenza protection among healthcare workers during the 2024/2025 A/H1N1 outbreak in Japan

Shohei Yamamoto[SUP] 1 [/SUP], Tetsuya Mizoue[SUP] 1 [/SUP], Mugen Ujiie[SUP] 2 [/SUP], Kumi Horii[SUP] 3 [/SUP], Junko S Takeuchi[SUP] 4 [/SUP], Maki Konishi[SUP] 1 [/SUP], Wataru Sugiura[SUP] 5 [/SUP], Norio Ohmagari[SUP] 6 [/SUP]



Affiliations
Abstract

Background: After the prolonged COVID-19 pandemic, during which the seasonal influenza epidemic was suppressed, Japan experienced a record-breaking influenza A/H1N1 outbreak in the 2024/2025 season. This situation also raises a concern about the immunogenicity of the annual inactivated influenza vaccine. This study evaluated post-vaccination hemagglutination inhibition (HI) antibody titers and their association with influenza infection risk among healthcare workers.
Methods: A serosurvey was conducted among staff at a national medical and research center in Tokyo in December 2024, one month after staff received the inactivated influenza vaccine. HI antibody titers against vaccine strains were measured, and participants were followed for influenza infection until January 2025. Seroprotection was defined as an HI titer ≥40. A Cox proportional hazards model assessed the association between HI titers and infection risk among vaccinated participants.
Results: Among 1,507 vaccinated participants, only 12.7% had seroprotective HI titers against A/H1N1. Around 90% had no influenza history for at least four seasons and had received repeated vaccinations over two seasons. Participants with HI titers <40 had a 4-fold higher infection risk than those with titers ≥40. A dose-response association was observed, even within the range below the titer of 40. Relative to titers <10, titers of 10 and 20 conferred 47.3% and 57.9% protection, respectively.
Conclusions: After a prolonged period without a major influenza epidemic, HI titers against A/H1N1 were extremely low in vaccinated healthcare workers. Nonetheless, higher post-vaccination HI titers, even at relatively low levels, were associated with protection, supporting the benefit of vaccines.

Keywords: Influenza; hemagglutination inhibition antibody; post-COVID-19; protection; vaccination.

 
Back
Top Bottom